메뉴 건너뛰기




Volumn 29, Issue 3, 2013, Pages 290-297

Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; BRIMONIDINE PLUS BRINZOLAMIDE; BRINZOLAMIDE;

EID: 84876810143     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0235     Document Type: Article
Times cited : (36)

References (17)
  • 1
    • 0033808223 scopus 로고    scopus 로고
    • The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators
    • The Advanced Glaucoma Intervention Study (AGIS): 7
    • The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130:429-440, 2000.
    • (2000) Am. J. Ophthalmol. , vol.130 , pp. 429-440
  • 3
    • 80051897270 scopus 로고    scopus 로고
    • Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study
    • Musch, D.C., Gillespie, B.W., Niziol, L.M., Lichter, P.R., and Varma, R. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118:1766-1773, 2011.
    • (2011) Ophthalmology , vol.118 , pp. 1766-1773
    • Musch, D.C.1    Gillespie, B.W.2    Niziol, L.M.3    Lichter, P.R.4    Varma, R.5
  • 5
    • 77749330689 scopus 로고    scopus 로고
    • Delaying treatment of ocular hypertension: The ocular hypertension treatment study
    • Kass, M.A., Gordon, M.O., Gao, F., et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 128:276-287, 2010.
    • (2010) Arch. Ophthalmol. , vol.128 , pp. 276-287
    • Kass, M.A.1    Gordon, M.O.2    Gao, F.3
  • 6
    • 0015947313 scopus 로고
    • Drop size and initial dosing frequency problems of topically applied ophthalmic drugs
    • Chrai, S.S., Makoid, M.C., Eriksen, S.P., and Robinson, J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci. 63:333-338, 1974.
    • (1974) J. Pharm. Sci. , vol.63 , pp. 333-338
    • Chrai, S.S.1    Makoid, M.C.2    Eriksen, S.P.3    Robinson, J.R.4
  • 8
    • 0036222151 scopus 로고    scopus 로고
    • Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication
    • DOI 10.1136/bjo.86.4.418
    • Pisella, P.J., Pouliquen, P., and Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 86:418-423, 2002. (Pubitemid 34293291)
    • (2002) British Journal of Ophthalmology , vol.86 , Issue.4 , pp. 418-423
    • Pisella, P.J.1    Pouliquen, P.2    Baudouin, C.3
  • 10
    • 69249214004 scopus 로고    scopus 로고
    • Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs
    • Bournias, T.E., and Lai, J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 116:1719-1724, 2009.
    • (2009) Ophthalmology , vol.116 , pp. 1719-1724
    • Bournias, T.E.1    Lai, J.2
  • 11
    • 44349161663 scopus 로고    scopus 로고
    • Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension
    • DOI 10.1185/030079908X301848
    • Day, D.G., and Hollander, D.A. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr. Med. Res. Opin. 24:1435-1442, 2008. (Pubitemid 351741577)
    • (2008) Current Medical Research and Opinion , vol.24 , Issue.5 , pp. 1435-1442
    • Day, D.G.1    Hollander, D.A.2
  • 12
    • 33646864300 scopus 로고    scopus 로고
    • A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension
    • DOI 10.1016/j.clinthera.2006.04.007, PII S0149291806000956
    • Reis, R., Queiroz, C.F., Santos, L.C., Avila, M.P., and Magacho, L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin. Ther. 28:552-559, 2006. (Pubitemid 43783448)
    • (2006) Clinical Therapeutics , vol.28 , Issue.4 , pp. 552-559
    • Reis, R.1    Queiroz, C.F.2    Santos, L.C.3    Avila, M.P.4    Magacho, L.5
  • 13
    • 0032169810 scopus 로고    scopus 로고
    • Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension
    • Brinzolamide Primary Therapy Study Group
    • Silver, L.H. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am. J. Ophthalmol. 126:400-408, 1998.
    • (1998) Am. J. Ophthalmol. , vol.126 , pp. 400-408
    • Silver, L.H.1
  • 14
    • 0034056845 scopus 로고    scopus 로고
    • The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
    • Brinzolamide Primary Therapy Study Group
    • Sall, K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv. Ophthalmol. 44 Suppl 2:S155-S162, 2000.
    • (2000) Surv. Ophthalmol. , vol.44 , Issue.SUPPL. 2
    • Sall, K.1
  • 15
    • 23944477451 scopus 로고    scopus 로고
    • Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension
    • DOI 10.1089/jop.2005.21.337
    • Craven, E.R., Walters, T.R., Williams, R., et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 21:337-348, 2005. (Pubitemid 41192905)
    • (2005) Journal of Ocular Pharmacology and Therapeutics , vol.21 , Issue.4 , pp. 337-348
    • Craven, E.R.1    Walters, T.R.2    Williams, R.3    Chou, C.4    Cheetham, J.K.5    Schiffman, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.